A Mini Library of Novel Triazolothiadiazepinylindole Analogues: Synthesis, Antioxidant and Antimicrobial Evaluations

Biradar, Jaiprakash Sharanappa; Rajesab, Parveen; Biradar, Naveen Jaiprakash; Somappa, Sasidhar Balappa

doi:https://doi.org/10.1155/2014/581737

The Scientific World Journal

On this page

Abstract Introduction Materials and Methods Results and Discussion Conclusions Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2014 | Article ID 581737 | https://doi.org/10.1155/2014/581737

A Mini Library of Novel Triazolothiadiazepinylindole Analogues: Synthesis, Antioxidant and Antimicrobial Evaluations

Jaiprakash Sharanappa Biradar,¹Parveen Rajesab,^1,2Naveen Jaiprakash Biradar,¹and Sasidhar Balappa Somappa^1,3

Academic Editor: M. Wujec, L. Previtera

Received23 Aug 2013

Accepted04 Dec 2013

Published20 Feb 2014

Abstract

A new series of novel triazolothiadiazepinylindole analogues were synthesized with an aim to examine possible antioxidant and antimicrobial activities. The titled compounds (3a–z) were obtained in good yield by reacting 5-(5-substituted-3-phenyl-1H-indol-2-yl)-4-amino-4H-1,2,4-triazole-3-thiols 1a–c with 3-(2,5-disubstituted-1H-indol-3-yl)-1(4-substituted phenyl)prop-2-en-1-ones 2a–i. All the newly synthesized compounds were characterized by IR, ¹H NMR, mass spectroscopic and analytical data. The synthesized analogues were tested for antioxidant and antimicrobial potency. Among the tested compounds 3a–c and 3j–l have shown very promising free radical scavenging activity and total antioxidant capacity. Compounds 3d–f, 3m–o, and 3s–z have shown excellent ferric reducing antioxidant activity. An outstanding antimicrobial activity is observed with compounds 3a–c and 3j–l.

1. Introduction

Antioxidants [1–3] act as “free radical scavengers” hence to prevent or slow the damage done by the free radicals [4–6]. Free-radical-induced oxidative stress associated with several cellular toxic processes including oxidative damage to protein, and DNA, membrane lipid oxidation, enzyme inactivation, and gene mutation leads to carcinogenesis [7]. Antioxidants are involved in processes such as immunity, protection against tissue damage, and reproduction and prevent growth or development caused by free radicals [8–10]. Antioxidants are useful in the prevention and treatment of Parkinson’s and Alzheimer’s disease [11–13].

Heterocycles constitute one of the major areas of organic chemistry and play important roles in drug discovery. Many of the best selling drugs currently in use contain one or more heterocyclic rings. Several fused heterocycles as well as biheterocycles are referred to as privileged structures [14]. Among them, sulfur- and nitrogen-containing heterocyclic compounds have maintained the interest of researchers and their unique structures led to several applications in different areas [15]. Triazoles and their derivatives constitute an important class of heterocyclic compounds and their analogues have been reported to possess various biological activities such as antimicrobial [16], anti-inflammatory [17], antihypertensive, anti-HIV [18], anticancer, and antitumor [19, 20]. Several compounds containing 1,2,4-triazole rings known as drugs like fluconazole, posaconazole, alprazolam, [21] and triazolothiadiazepine analogues represent a well-known class of drug substances at different stages of research, which possess antiviral [22] and antimicrobial properties [23].

Indole is a heterocycle of great importance in biological systems [24, 25]. The indole moiety is present in a number of drugs currently [26] in the market; in our previous approaches, we have described some new indole analogues with highly potent antioxidant, DNA cleavage and antimicrobial activities [27–30].

Interestingly, we have developed a new green protocol for the synthesis of rapid and clean synthetic route towards mini library of triazolothiadiazepinylindole analogues, which showed in vitro antioxidant and antimicrobial activities.

2. Materials and Methods

2.1. Chemistry

All chemicals used in this investigation were of analytical grade and were purified whenever necessary. Melting points of the synthesized compounds were measured in open capillaries and are uncorrected. Reactions were monitored by thin-layer chromatography (TLC) on silica gel 60 F₂₅₄ aluminium sheets (MERCK). Iodine vapour was used as detecting agent. IR spectra were recorded in KBr on PerkinElmer and FTIR spectrophotometer ( in cm⁻¹). ¹H NMR and ¹³C NMR spectra on BRUKER AVENCE II 400-MHz NMR spectrometer and the chemical shifts were expressed in ppm ( scale) downfield from TMS as an internal reference. The mass spectra were recorded on LC-MSD-Trap-SL instrument. The elemental analysis was performed by using FLASH EA 1112 SERIES instrument.

2.1.1. General Procedure for the Synthesis of Compounds 1a–c

The precursors 5-(5-substituted-3-phenyl-1H-indol-2-yl)-4-amino-4H-1,2,4-triazole-3-thiols) (1a–c) were obtained from 3,5-disubstituted indol-2-carboxyhydrazides by reported method [31].

2.1.2. General Procedure for the Synthesis of Compounds 2a–i

3-(2,5-disubstituted-1H-indol-3-yl)-1(4-substituted phenyl) prop-2-en-1-one 2a–i were prepared by reported method [29] by reacting disubstituted indole aldehydes with substituted acetophenone in the presence of piperidine in good yields.

2.1.3. General Procedure for the Synthesis of Compounds 3a–z

(1) Conventional Method. To a solution of substituted indolyl- triazole 1a–c (0.01 mol) in acetic acid substituted chalcones 2a–i (0.01 mol) were added. The reaction mixture was refluxed 3-4 hrs. The completion of the reaction was monitored by TLC. After the completion, the reaction mixture was poured to a beaker containing 100 mL of ice-cold water. The crude products thus separated were filtered and recrystallized from ethanol to yield target compounds 3a–z.

(2) Microwave Oven Method. A mixture of substituted indolyl triazole 1a–c (0.01 mol) and substituted chalcones 2a–i (0.01 mol) was powdered, mixed, and introduced to borosil sample crucible containing few drops of acetic acid. This was subjected to microwave irradiation for 10 minutes with 70% microwave power. After the completion (TLC), reaction mixture was brought to room temperature, washed with ethanol, and recrystallized to get the title compounds 3a–z which were found to be in good purity (TLC) and excellent yield.

8-(5-Chloro-2-phenyl-1H-indol-3-yl)-3-(5-chloro-3-phenyl-1H-indol-2-yl)-6-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3a). IR (KBr) (cm⁻¹): 3180, 3090, 1654, 1624, 1546; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 12.47 (s, 1H, indole NH), 11.63 (s, 1H, indole NH), 7.31–8.23 (m, 20H, Ar-H), 5.65 (s, 1H, –CH=); ¹³C NMR (DMSO-d₆+ CDCl₃) (ppm): 108, 111, 113, 117, 118, 118, 118, 120, 123, 125, 126, 126, 126, 128, 128, 128, 128, 129, 129, 129, 130, 132, 133, 134, 135, 138, 138, 144, 145, 166. MS: m/z = 712 , 714 [M+2], 718 [M+4], 720 [M+6]; Anal. calcd. for (C₃₉H₂₃N₆Cl₃S): C, 65.60; H, 3.25; N, 11.77%. Found: C, 65.59; H, 3.21; N, 11.75%.

8-(5-Chloro-2-phenyl-1H-indol-3-yl)-3-(5-chloro-3-phenyl-1H-indol-2-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3b). IR (KBr) (cm⁻¹): 3189, 3049, 1608, 1579, 1553; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.15 (s, 1H, indole NH), 10.25 (s, 1H, indole NH), 7.29–8.72 (m, 21H, Ar-H), 4.95 (s, 1H, –CH=); MS: m/z = 678 , 680 [M+2], 682 [M+4]; Anal. calcd. for (C₃₉H₂₄N₆Cl₂S): C, 68.92; H, 3.56; N, 12.37%. Found: C, 68.81; H, 3.52; N, 12.31%.

8-(5-Chloro-2-phenyl-1H-indol-3-yl)-3-(5-chloro-3-phenyl-1H-indol-2-yl)-6-(4-methylphenyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3c). IR (KBr) (cm⁻¹): 3108, 3053, 1606, 1574, 1553; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.03 (s, 1H, indole NH), 10.03 (s, 1H, indole NH), 7.29–8.14 (m, 20H, Ar-H), 5.35 (s, 1H, –CH=), 2.44 (s, 3H, CH₃); MS: m/z = 692 , 694 [M+2], 696 [M+4]; Anal. calcd. for (C₄₀H₂₆N₆Cl₂S): C, 69.26; H, 3.78; N, 12.12%. Found: C, 69.15; H, 3.69; N, 12.21%.

3-(5-Chloro-3-phenyl-1H-indol-2-yl)-6-(4-chlorophenyl)-8-(5-methyl-2-phenyl-1H-indol-3-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3d). IR (KBr) (cm⁻¹): 3391, 3265, 1601, 1540, 1519; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.43 (s, 1H, indole NH), 10.85 (s, 1H, indole NH), 6.40–9.13 (m, 20H, Ar-H), 4.91 (s, 1H, –CH=), 2.66 (s, 3H, CH₃); MS: m/z = 692 , 694 [M+2], 696 [M+4]; Anal. calcd. for (C₄₀H₂₆N₆Cl₂S): C, 69.26; H, 3.78; N, 12.12%. Found: C, 69.15; H, 3.69; N, 12.21%.

3-(5-Chloro-3-phenyl-1H-indol-2-yl)-8-(5-methyl-2-phenyl-1H-indol-3-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3e). IR (KBr) (cm⁻¹): 3106, 2996, 1650, 1590, 1560; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.01 (s, 1H, indole NH), 10.12 (s, 1H, indole NH), 6.40–8.58 (m, 21H, Ar-H), 4.91 (s, 1H, –CH=), 2.55 (s, 3H, CH₃); MS: m/z = 658 , 660 [M+2]; Anal. calcd. for (C₄₀H₂₇N₆ClS): C, 72.88; H, 4.13; N, 12.75%. Found: C, 72.75; H, 4.09; N, 12.64%.

3-(5-Chloro-3-phenyl-1H-indol-2-yl)-8-(5-methyl-2-phenyl-1H-indol-3-yl)-6-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3f). IR (KBr) (cm⁻¹): 3443, 3133, 1602, 1578, 1558; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.31 (s, 1H, indole NH), 10.25 (s, 1H, indole NH), 7.11–8.18 (m, 20H, Ar-H), 5.29 (s, 1H, –CH=), 2.54 (s, 3H, CH₃), 2.43 (s, 3H, CH₃); MS: m/z = 672 , 674 [M+2]; Anal. calcd. for (C₄₁H₂₉N₆ClS): C, 73.15; H, 4.34; N, 12.48%. Found: C, 73.02; H, 4.29; N, 12.37%.

3-(5-Chloro-3-phenyl-1H-indol-2-yl)-6-(4-chlorophenyl)-8-(1H-indol-3-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3g). IR (KBr) (cm⁻¹): 3239, 3098, 1607, 1578, 1553; ¹H NMR (DMSO-d₆+ CDCl₃) δ (ppm): 11.78 (s, 1H, indole NH), 10.51 (s, 1H, indole NH), 6.40–8.56 (m, 17H, Ar-H), 4.94 (s, 1H, –CH=); MS: m/z = 602 , 604 [M+2], 606 [M+4]; Anal. calcd. for (C₃₃H₂₀N₆Cl₂S): C, 65.67; H, 3.34; N, 13.92; Found: C, 65.57; H, 3.28; N, 13.85%.

3-(5-Chloro-3-phenyl-1H-indol-2-yl)-8-(1H-indol-3-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3h). IR (KBr) (cm⁻¹): 3404, 3104, 1608, 1558, 1505; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 10.61 (s, 1H, indole NH), 10.01 (s, 1H, indole NH), 6.43–8.91 (m, 18H, Ar-H), 5.15 (s, 1H, –CH=); MS: m/z = 568 , 570 [M+2]; Anal. calcd. for (C₃₃H₂₁N₆ClS): C, 69.65; H, 3.72; N, 14.77%. Found: C, 69.55; H, 3.65; N, 14.71%.

3-(5-Chloro-3-phenyl-1H-indol-2-yl)-8-(1H-indol-3-yl)-6-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3i). IR (KBr) (cm⁻¹): 3160, 3096, 1645, 1603; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.97 (s, 1H, indole NH), 11.39 (s, 1H, indole NH), 6.80–7.85 (m, 17H, Ar-H), 5.59 (s, 1H, –CH=), 2.64 (s, 3H, CH₃); MS: m/z = 582 , 584 [M+2]; Anal. calcd. for (C₃₄H₂₃N₆ClS): C, 70.03; H, 3.98; N, 14.41%. Found: C, 69.91; H, 3.95; N, 14.31%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-8-(5-chloro-2-phenyl-1H-indol-3-yl)-6-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3j). IR (KBr) (cm⁻¹): 3148, 3098, 1643, 1589, 1551; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 12.48 (s, 1H, indole NH), 11.99 (s, 1H, indole NH), 7.07–8.23 (m, 20H, Ar-H), 5.60 (s, 1H, –CH=); MS: m/z = 756 , 758 [M+2], 760 [M+4], 762 [M+6]; Anal. calcd. for (C₃₉H₂₃N₆BrCl₂S): C, 61.75; H, 3.06; N, 11.08%. Found: C, 61.69; H, 3.01; N, 10.91%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-8-(5-chloro-2-phenyl-1H-indol-3-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3k). IR (KBr) (cm⁻¹): 3158, 3068, 1590, 1576, 1551; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.15 (s, 1H, indole NH), 10.05 (s, 1H, indole NH), 7.29–8.72 (m, 21H, Ar-H), 5.45 (s, 1H, –CH=); MS: m/z = 722 , 724 [M+2], 726 [M+4]; Anal. calcd. for (C₃₉H₂₄N₆BrClS): C, 64.69; H, 3.34; N, 11.61%. Found: C, 65.21; H, 3.51; N, 11.45%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-8-(5-chloro-2-phenyl-1H-indol-3-yl)-6-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3l). IR (KBr) (cm⁻¹): 3108, 3029, 1644, 1606, 1553; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.03 (s, 1H, indole NH), 10.33 (s, 1H, indole NH), 7.2–8.1 (m, 20H, Ar-H), 5.05 (s, 1H, –CH=), 2.44 (s, 3H, CH₃); MS: m/z = 736 , 738 [M+2], 740 [M+4]; Anal. calcd. for (C₄₀H₂₆N₆BrClS): C, 65.09; H, 3.55; N, 11.39%. Found: C, 64.89; H, 3.51; N, 11.28%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-6-(4-chlorophenyl)-8-(5-methyl-2-phenyl-1H-indol-3-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3m). IR (KBr) (cm⁻¹): 3176, 3048, 1623, 1584, 1509; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 12.20 (s, 1H, indole NH), 11.15 (s, 1H, indole NH), 6.32–8.13 (m, 20H, Ar-H), 5.60 (s, 1H, –CH=), 1.74 (s, 3H, CH₃); MS: m/z = 736 , 738 [M+2], 740 [M+4]; Anal. calcd. for (C₄₀H₂₆N₆BrClS): C, 65.09; H, 3.55; N, 11.39%. Found: C, 64.09; H, 3.51; N, 11.28%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-8-(5-methyl-2-phenyl-1H-indol-3-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3n). IR (KBr) (cm⁻¹): 3240, 3198, 1604, 1558, 1553; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.01 (s, 1H, indole NH), 9.90 (s, 1H, indole NH), 6.40–8.58 (m, 21H, Ar-H), 4.31 (s, 1H, –CH=), 2.55 (s, 3H, CH₃); MS: m/z = 702 , 704 [M+2]; Anal. calcd. for (C₄₀H₂₇N₆BrS): C, 68.28; H, 3.87; N, 11.94%. Found: C, 68.18; H, 3.82; N, 11.83%.

3-(5-bromo-3-phenyl-1H-indol-2-yl)-8-(5-methyl-2-phenyl-1H-indol-3-yl)-6-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3o). IR (KBr) (cm⁻¹): 3117, 3047, 1641, 1606, 1573; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 10.25 (s, 1H, indole NH), 9.95 (s, 1H, indole NH), 7.11–8.18 (m, 20H, Ar-H), 5.15 (s, 1H, –CH=), 2.54 (s, 3H, CH₃), 2.43 (s, 3H, CH₃); MS: m/z = 716 , 718 [M+2]; Anal. calcd. for (C₄₁H₂₉N₆BrS): C, 68.62; H, 4.07; N, 11.71%. Found: C, 68.52; H, 4.05; N, 11.59%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-6-(4-chlorophenyl)-8-(1H-indol-3-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3p). IR (KBr) (cm⁻¹): 3167, 3047, 1648, 1589, 1558; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 10.61 (s, 1H, indole NH), 10.23 (s, 1H, indole NH), 6.83–8.19 (m, 17H, Ar-H), 5.19 (s, 1H, –CH=); MS: m/z = 646 , 648 [M+2], 650 [M+4]; Anal. calcd. for (C₃₃H₂₀N₆BrClS): C, 61.17; H, 3.11; N, 12.97%. Found: C, 61.12; H, 3.09; N, 12.85%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-8-(1H-indol-3-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3q). IR (KBr) (cm⁻¹): 3097, 2998, 1606, 1578, 1551; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.01 (s, 1H, indole NH), 10.01 (s, 1H, indole NH), 6.83–8.91 (m, 18H, Ar-H), 5.15 (s, 1H, –CH=); MS: m/z = 612 , 614 [M+2]; Anal. calcd. For (C₃₃H₂₁N₆BrS): C, 64.60; H, 3.45; N, 13.70%. Found: C, 64.56; H, 3.41; N, 13.51%.

3-(5-Bromo-3-phenyl-1H-indol-2-yl)-8-(1H-indol-3-yl)-6-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3r). IR (KBr) (cm⁻¹): 3104, 3049, 1608, 1598, 1558; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.07 (s, 1H, indole NH), 10.19 (s, 1H, indole NH), 6.80–7.85 (m, 17H, Ar-H), 5.39 (s, 1H, –CH=) 2.64 (s, 3H, CH₃); MS: m/z = 626 , 628 [M+2]; Anal. calcd. for (C₃₄H₂₃N₆BrS): C, 65.07; H, 3.69; N, 13.39%. Found: C, 64.95; H, 3.65; N, 13.28%.

8-(5-Chloro-2-phenyl-1H-indol-3-yl)-6-(4-chlorophenyl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3s). IR (KBr) (cm⁻¹): 3219, 3196, 1641, 1589, 1552; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.01 (s, 1H, indole NH), 10.25 (s, 1H, indole NH), 6.40–8.59 (m, 20H, Ar-H), 4.95 (s, 1H, –CH=), 2.56 (s, 3H, CH₃); MS: m/z = 692 , 694 [M+2], 696 [M+4]; Anal. calcd. for (C₄₀H₂₆N₆Cl₂S): C, 69.26; H, 3.78; N, 12.12%. Found: C, 69.14; H, 3.72; N, 12.02%.

8-(5-Chloro-2-phenyl-1H-indol-3-yl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3t). IR (KBr) (cm⁻¹): 3244, 3189, 1641, 1604, 1552; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 12.39 (s, 1H, indole NH), 11.09 (s, 1H, indole NH), 6.80–7.85 (m, 21H, Ar-H), 5.15 (s, 1H, –CH=), 2.76 (s, 3H, CH₃); MS: m/z = 658 , 660 [M+2]; Anal. calcd. for (C₄₀H₂₇N₆ClS): C, 72.88; H, 4.13; N, 12.75%. Found: C, 72.78; H, 4.10; N, 12.59%.

8-(5-Chloro-2-phenyl-1H-indol-3-yl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-6-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3u). IR (KBr) (cm⁻¹): 3248, 3198, 1606, 1579, 1552; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 12.20 (s, 1H, indole NH), 11.98 (s, 1H, indole NH), 7.05–8.13 (m, 20H, Ar-H), 4.37 (s, 1H, –CH=), 2.57 (s, 3H, CH₃), 2.01 (s, 3H, CH₃); MS: m/z = 672 , 674 [M+2]; Anal. calcd. for (C₄₁H₂₉N₆ClS): C, 73.15; H, 4.34; N, 12.48%. Found: C, 73.28; H, 4.31; N, 12.36%.

6-(4-Chlorophenyl)-8-(5-methyl-2-phenyl-1H-indol-3-yl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3v). IR (KBr) (cm⁻¹): 3248, 3198, 1604, 1574, 1552; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.39 (s, 1H, indole NH), 10.39 (s, 1H, indole NH), 6.43–8.91 (m, 20H, Ar-H), 4.55 (s, 1H, –CH=), 2.58 (s, 3H, CH₃); MS: m/z = 672 , 674 [M+2]; Anal. calcd. for (C₄₁H₂₉N₆ClS): C, 73.15; H, 4.34; N, 12.48%. Found: C, 73.28; H, 4.31; N, 12.36%.

8-(5-Methyl-2-phenyl-1H-indol-3-yl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3w). IR (KBr) (cm⁻¹): 3248, 3179, 1604, 1574, 1556; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.05 (s, 1H, indole NH), 10.10 (s, 1H, indole NH), 6.32–8.13 (m, 21H, Ar-H), 5.60 (s, 1H, –CH=), 2.23 (s, 6H, CH₃); MS: m/z = 638 ; Anal. calcd. For (C₄₁H₃₀N₆S): C, 77.09; H, 4.73; N, 13.16%. Found: C, 77.06; H, 4.68; N, 13.03%.

8-(5-Methyl-2-phenyl-1H-indol-3-yl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-6-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3x). IR (KBr) (cm⁻¹): 3184, 3148, 1606, 1574, 1553; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 11.05 (s, 1H, indole NH), 10.07 (s, 1H, indole NH), 6.40–8.77 (m, 20H, Ar-H), 4.15 (s, 1H, –CH=), 2.54 (s, 6H, CH₃), 2.31 (s, 3H, CH₃); MS: m/z = 652 ; Anal. calcd. for (C₄₂H₃₂N₆S): C, 77.27; H, 4.94; N, 12.87%. Found: C, 77.17; H, 4.91; N, 12.96%.

8-(1H-Indol-3-yl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3y). IR (KBr) (cm⁻¹): 3354, 3258, 1674, 1595, 1554; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 10.61 (s, 1H, indole NH), 10.01 (s, 1H, indole NH), 6.40–8.91 (m, 18H, Ar-H), 4.85 (s, 1H, –CH=), 2.54 (s, 3H, CH₃); MS: m/z = 548 ; Anal. calcd. for (C₃₄H₂₄N₆S): C, 74.43; H, 4.41; N, 15.32%. Found: C, 74.39; H, 4.39; N, 15.25%.

6-(4-Chlorophenyl)-8-(1H-indol-3-yl)-3-(5-methyl-3-phenyl-1H-indol-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine (3z). IR (KBr) (cm⁻¹): 3391, 3244, 1667, 1601, 1540; ¹H NMR (DMSO-d₆+ CDCl₃) (ppm): 12.23 (s, 1H, indole NH), 10.11 (s, 1H, indole NH), 6.76–7.61 (m, 17H, Ar-H), 4.37 (s, 1H, –CH=), 2.08 (s, 3H, CH₃); MS: m/z = 582 584 [M+2]; Anal. calcd. For (C₃₄H₂₅N₆S): C, 70.03; H, 3.98; N, 14.41%. Found: C, 69.98; H, 3.95; N, 14.35%.

2.2. Biological Activities

2.2.1. Antioxidant Activities

(1) Free Radical Scavenging Activity. Free radical scavenging activity was done by DPPH method [32]. Different concentrations (25 μg, 50 μg, and 100 μg) of samples and butylated hydroxy anisole (BHA) were taken in different test tubes. The volume was adjusted to 100 μL by adding MeOH. Five milliliters of 0.1 mM methanolic solution of DPPH was added to these tubes and shaken vigorously. The tubes were allowed to stand at 27°C for 20 min. The control was prepared as above without any samples. The absorbances of samples were measured at 517 nm. Radical scavenging activity was calculated using the following formula:

(2) Total Antioxidant Capacity. Various concentrations of samples (25 μg, 50 μg, and 100 μg) were taken in a series of test tubes. To this, 1.9 mL of reagent solution (0.6 M sulfuric acid, 28 mM sodium phosphate, and 4 mM ammonium molybdate) was added. The tubes were incubated at 95°C for 90 min and allowed to cool. The absorbance of each aqueous solution was measured at 695 nm against a blank. Antioxidant capacities are expressed as equivalents of ascorbic acid. Ascorbic acid equivalents were calculated using standard graph of ascorbic acid. The values are expressed as ascorbic acid equivalents in μg per mg of samples.

(3) Ferric Reducing Antioxidant Power. Various concentrations of samples (25 μg, 50 μg, and 100 μg) were mixed with 2.5 mL of 200 mmol/L sodium phosphate buffer (pH 6.6) and 2.5 mL of 1% potassium ferricyanide. The mixture was incubated at 50°C for 20 min. Next, 2.5 mL of 10% trichloroacetic acid (w/v) was added. From this solution, 5 mL was mixed with 5 mL of distilled water and 1 mL of 0.1% ferric chloride and absorbance was measured spectrophotometrically at 700 nm. BHA was used as standard.

2.3. Antimicrobial Activity

Series of novel indole analogues are tested for in vitro antimicrobial activity against gram-negative bacteria Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 33499 and gram-positive bacteria Staphylococcus aureus ATCC 6538 and antifungal activity against Candida tropicalis ATCC 8302 and Candida albicans ATCC 60193by applying the agar plate diffusion technique [33]. Dilution process was adopted at 25 μg, 50 μg, and 100 μg/mL concentrations, respectively. The activity is compared with reference drugs gentamycin for antibacterial and fluconazole for antifungal activity. The zone of inhibition after 24 hr of incubation at 37°C in case of antibacterial activity and 48 hr in case of antifungal activity was compared with that of standards.

3. Results and Discussion

3.1. Chemistry

Molecules were designed with the aim of exploring their antioxidant and antimicrobial activities. The target compounds were synthesized as outlined in (Scheme 1). 3,5-Disubstitutedindole-2-carboxyhydrazides were reacted with carbon disulphide in the presence of base and hydrazine hydrate to get 5-(5-substituted-3-phenyl-1H-indol-2-yl)-4-amino-4H-1,2,4-triazole-3-thiols 1a–c. Claisen-Schmidt condensation of 2,5-disubstituted indole-3-carboxaldehydes with substituted acetophenones produced 3-(2,5-disubstituted-1H-indol-3-yl)-1-(4-substituted-phenyl)prop-2-en-1-one 2a–i. The synthesized compounds 3a–z were obtained in good yield by cyclocondensation of 5-(5-substituted-3-phenyl-1H-indol-2-yl)-4-amino-4H-1,2,4-triazole-3-thiol 1a–c with 3-(2,5-disubstituted-1H-indol-3-yl)-1(4-substituted phenyl)prop-2-en-1-one 2a–i. The formation of products was monitored by TLC. All the newly synthesized compounds were characterized by IR, ¹H NMR, ¹³C NMR, mass spectroscopic and analytical data. The IR spectrum of 8-(5-chloro-2-phenyl-1H-indol-3-yl)-3-(5-chloro-3-phenyl-1H-indol-2-yl)-6-(3-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine 3a showed a strong absorption at 3180 cm⁻¹ and 3090 cm⁻¹ corresponding to indole NH, absorption at 1654 and 1624, corresponding to triazole C=N, and absorption at 1546 cm⁻¹ corresponding to thiadiazepine C=N stretching, respectively. The ¹H NMR spectrum of 3a has exhibited a singlet at 12.47 ppm due to indole NH and peak at 11.63 ppm is due to indole NH which is also D₂O exchangeable. A multiplet between 7.31–8.47 ppm corresponds to twenty aromatic protons present in the molecule and a peak at 5.65 ppm is assigned for the –CH= of thiadiazepine ring proton. The ¹³C NMR spectrum of compound 3a has shown peaks at δ 108, 111, 113, 117, 118, 118, 118, 120, 123, 125, 126, 126, 126, 128, 128, 128, 128, 129, 129, 129, 130, 132, 133, 134, 135, 138, 138, 144, 145, and 166. The mass spectrum of compound 3a has shown molecular ion peak at m/z 712 which is corresponding to molecular weight of the compound. The above spectral data supports the formation of compound 3a.

Various new triazolothiadiazepinylindole analogues synthesized during the present investigation are listed in (Table 1).

3.2. Biological Activities

The compounds 3a–z were screened for their antioxidant (free radical scavenging, total antioxidant capacity, and ferric reducing antioxidant power) and antimicrobial activities.

3.2.1. Antioxidant Activities

(1) Free Radical Scavenging Activity. The target compounds were screened for free radical scavenging activity by DPPH method [32]. The samples were prepared at concentrations of 25, 50, and 100 μg/100 μL and butylated hydroxy anisole (BHA) was taken as standard. DPPH is a stable free radical in a methanolic solution. Because of the unpaired electron of DPPH, it gives a strong absorption maxima at 517 nm in the visible region (purple color). In addition, the unpaired electron of the radical becomes paired in the presence of a hydrogen donor (a free radical scavenging antioxidant), decreasing the absorption. Among the compounds tested 3a–c and 3j–l have shown very promising free radical scavenging activity. The increased activity is due to the existence of halogen substitution at the five positions of both indoles. The hydrogen of indole NH could be donated to the DPPH to form DPPH free radical; by the presence of phenyl ring at the third position of indole, the DPPH free radical will be stabilized by the resonance. Compounds 3d–f, 3m–o, and 3s–x containing halogen atom at five positions of indole and a methyl group at another indole ring have shown moderate activity, whereas compounds 3g–i, 3p–r, and 3y–z have shown the least activity compared with the standard. The bar graph representation of percentage of free radical scavenging activity is displayed in Figures 1 and 2.

(2) Total Antioxidant Capacity. Total antioxidant activity was performed to all the newly synthesized compounds [34]. Antioxidant capacities are expressed as equivalents of ascorbic acid. Among the tested compounds 3a–c and 3j–l which are halogen substituted triazolothiadiazepinylindole have shown very strong total antioxidant capacity. Compounds with methyl substitution at the fifth position of the indole ring and no substitution at the second and fifth positions have shown the least total antioxidant capacity compared with the standard. The increased activity is due to the presence of halogen at the fifth position and a phenyl ring at the third position of indole. The results of total antioxidant activity are shown in Figures 3 and 4.

(3) Ferric Reducing Antioxidant Power Activity. The novel compounds were screened for ferric reducing antioxidant activity [35]. Butylated hydroxy anisole (BHA) was used as standard. All the tested compounds have shown positive tendency towards the ferric reducing activity. The presence of reducer (i.e., antioxidant) causes the reduction of the Fe⁺³/ferricyanide complex to the Fe⁺² form after the addition of trichloroacetic acid and ferric chloride. The reducing power of test compounds increases with increase in concentration. Compounds 3d–f, 3m–o, and 3s–z have shown excellent ferric reducing antioxidant activity and other analogues of indole have shown moderate to high activity. The presence of methyl group at the fifth position of the indole ring plays an important role as a better electron donor which enhances reducing power activity of the compounds. The results are presented in Figures 5 and 6.

3.3. Antimicrobial Activity

Applying the agar plate diffusion technique [33], series of novel triazolothiadiazepinylindole analogues were screened for in vitro antibacterial activity against (Table 2) gram-negative bacteria Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) and gram-positive bacteria Staphylococcus aureus (S. aureus) at 25 μg/mL, 50 μg/mL, and 100 μg/mL concentrations, respectively. Gentamycin was used as standard. The zone of inhibitions was measured in mm for each concentration. Most of the screened compounds were found to have significant antibacterial activity. Compounds 3a–c and 3j–l have shown very good activity against all the three bacterial strains. Compounds 3d–f, 3m–o, and 3s–x have shown moderate activity and compounds 3g–i, 3p–r, and 3y–z have shown the least activity. Antifungal screening of the compounds was carried out in vitro against two fungi strains Candida tropicalis and Candida albicans at 25 μg/mL, 50 μg/mL, and 100 μg/mL concentrations using fluconazole as standard. Among the tested indole analogues the majority of compounds exhibited moderate to significant antifungal activity.

4. Conclusions

We have synthesized titled compounds 3a–z by economic, better yield, and safer methods through the formation of compounds 1a–c and 2a–i under thermal and microwave condition. The compounds 3a–z were subjected for their antioxidant and antimicrobial screening. Very potent antimicrobial, scavenging and antioxidant activity was observed with compounds containing halogens at the fifth position of indoles. Excellent ferric reducing activity was observed with compounds containing electron donor group at five positions of one/both indoles. Therefore, the findings will provide a great impact on chemists and biochemists for further investigations in the indole field in search of molecules possessing potent antioxidant and antimicrobial activities.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank the Department of Chemistry, Gulbarga University, Gulbarga. The authors are also thankful to the director of IISc (Bangalore) and IIT (Madras) for spectroscopic analysis. They also extend their sincere thanks to BIOGENICS, Hubli, and Department of Microbiology, Gulbarga University, Gulbarga, for their assistance in carrying out biological activities.

References

S. V. Lennon, S. J. Martin, and T. G. Cotter, “Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli,” Cell Proliferation, vol. 24, no. 2, pp. 203–214, 1991.
View at: Google Scholar
H. Shirinzadeh, B. Eren, H. Gurer-Orhan, S. Suzen, and S. Özden, “Novel indole-based analogs of melatonin: synthesis and in vitro antioxidant activity studies,” Molecules, vol. 15, no. 4, pp. 2187–2202, 2010.
View at: Publisher Site | Google Scholar
M. L. Circu and T. Y. Aw, “Reactive oxygen species, cellular redox systems, and apoptosis,” Free Radical Biology and Medicine, vol. 48, no. 6, pp. 749–762, 2010.
View at: Publisher Site | Google Scholar
Y. Hangun-Balkir and M. L. McKenney, “Determination of antioxidant activities of berries and resveratrol,” Green Chemistry Letters and Reviews, vol. 5, no. 2, pp. 147–153, 2012.
View at: Publisher Site | Google Scholar
F. Regoli and G. Principato, “Glutathione, glutathione-dependent and antioxidant enzymes in mussel, Mytilus galloprovincialis exposed to metals under field and laboratory conditions: implications for the use of biochemical biomarkers,” Aquatic Toxicology, vol. 31, no. 2, pp. 143–164, 1995.
View at: Publisher Site | Google Scholar
N. Topalca, E. Yegin, and I. Celik, “Influence of indole-3-butyric acid on antioxidant defense systems in various tissues of rats at subacute and subchronic exposure,” Food and Chemical Toxicology, vol. 47, no. 10, pp. 2441–2444, 2009.
View at: Publisher Site | Google Scholar
H. E. Poulsen, H. Prieme, and S. Loft, “Role of oxidative DNA damage in cancer initiation and promotion,” European Journal of Cancer Prevention, vol. 7, no. 1, pp. 9–16, 1998.
View at: Google Scholar
M. Liu, X. Q. Li, C. Weber, C. Y. Lee, J. Brown, and R. H. Liu, “Antioxidant and antiproliferative activities of raspberries,” Journal of Agricultural and Food Chemistry, vol. 50, no. 10, pp. 2926–2930, 2002.
View at: Publisher Site | Google Scholar
B. Halliwell, “Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment,” Drugs & Aging, vol. 18, no. 9, pp. 685–716, 2001.
View at: Google Scholar
K. Sudha, A. Rao, S. Rao, and A. Rao, “Free radical toxicity and antioxidants in Parkinson's disease,” Neurology India, vol. 51, no. 1, pp. 60–62, 2003.
View at: Google Scholar
G. S. Yossi, M. Eldad, and O. Daniel, “Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier,” Neuropharmacology, vol. 40, no. 8, pp. 959–975, 2001.
View at: Publisher Site | Google Scholar
K. Asplund, “Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review,” Journal of Internal Medicine, vol. 251, no. 5, pp. 372–392, 2002.
View at: Publisher Site | Google Scholar
K. N. Prasad, W. C. Cole, and B. Kumar, “Multiple antioxidants in the prevention and treatment of Parkinson's disease,” Journal of the American College of Nutrition, vol. 18, no. 5, pp. 413–423, 1999.
View at: Google Scholar
C. Li-Hsun, C. Chia-Mao, B. S. Deepak, and S. Chung-Ming, “Divergent synthesis of unsymmetrical annulated biheterocyclic compound libraries: benzimidazole linked indolo-benzodiazepines/quinoxaline,” ACS Combinatorial Science, vol. 13, no. 4, pp. 391–398, 2011.
View at: Publisher Site | Google Scholar
M. García-Valverde and T. Torroba, “Special issue: sulfur-nitrogen heterocycles,” Molecules, vol. 10, no. 2, pp. 318–320, 2005.
View at: Google Scholar
T. Karabasanagouda, A. V. Adhikari, and N. S. Shetty, “Synthesis and antimicrobial activities of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines carrying thioalkyl and sulphonyl phenoxy moieties,” European Journal of Medicinal Chemistry, vol. 42, no. 4, pp. 521–529, 2007.
View at: Publisher Site | Google Scholar
M. D. Mullican, M. W. Wilson, D. T. Connor, C. R. Kostlan, D. J. Schrier, and R. D. Dyer, “Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents,” Journal of Medicinal Chemistry, vol. 36, no. 8, pp. 1090–1099, 1993.
View at: Google Scholar
T. Wen-Jie and H. Yong-Zhou, “Simple and efficient one-pot synthesis of 2,4-diaryl-1,2,3-triazoles,” Synthetic Communications, vol. 36, no. 17, pp. 2461–2468, 2006.
View at: Publisher Site | Google Scholar
Y. A. Al-Soud, N. A. Al-Masoudi, and A. R. Ferwanah, “Synthesis and properties of new substituted 1,2,4-triazoles: potential antitumor agents,” Bioorganic & Medicinal Chemistry, vol. 11, no. 8, pp. 1701–1708, 2003.
View at: Publisher Site | Google Scholar
B. S. Holla, B. Veerendra, M. K. Shivananda, and B. Poojary, “Synthesis characterization and anticancer activity studies on some Mannich bases derived from 1,2,4-triazoles,” European Journal of Medicinal Chemistry, vol. 38, no. 7-8, pp. 759–767, 2003.
View at: Publisher Site | Google Scholar
S. F. Barbuceanu, G. L. Almajan, I. Saramet, C. Draghici, R. Socoteanu, and F. Barbuceanu, “New S-alkylated 1,2,4-triazoles incorporating diphenyl sulfone moieties with potential antibacterial activity,” Journal of the Serbian Chemical Society, vol. 74, no. 10, pp. 1041–1049, 2009.
View at: Publisher Site | Google Scholar
A.-R. Farghaly, E. De Clercq, and H. El-Kashef, “Synthesis and antiviral activity of novel [1,2,4]triazolo[3,4-b][1,3,4] thiadiazoles, [1,2,4]triazolo[3,4-b][1,3,4] thiadiazines and [1,2,4]triazolo[3,4-b] [1,3,4] thiadiazepines,” Arkivoc, vol. 2006, no. 10, pp. 137–151, 2006.
View at: Publisher Site | Google Scholar
M. Kidwai, P. Sapra, P. Misra, R. Saxena, and M. Singh, “Microwave assisted solid support synthesis of novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazepines as potent antimicrobial agents,” Bioorganic & Medicinal Chemistry, vol. 9, no. 2, pp. 217–220, 2001.
View at: Publisher Site | Google Scholar
E. R. Abbey, L. N. Zakharov, and S.-Y. Liu, “Boron in disguise: the parent fused BN indole,” Journal of the American Chemical Society, vol. 133, no. 30, pp. 11508–11511, 2011.
View at: Publisher Site | Google Scholar
F.-R. Alexandre, A. Amador, S. Bot et al., “Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors,” Journal of Medicinal Chemistry, vol. 54, no. 1, pp. 392–395, 2011.
View at: Publisher Site | Google Scholar
A. J. Kochanowska-Karamyan and M. T. Hamann, “Marine indole alkaloids: potential new drug leads for the control of depression and anxiety,” Chemical Reviews, vol. 110, no. 8, pp. 4489–4497, 2010.
View at: Publisher Site | Google Scholar
B. S. Sasidhar and J. S. Biradar, “Synthesis of some bisindolyl analogs for in vitro cytotoxic and DNA cleavage studies,” Medicinal Chemistry Research, vol. 22, no. 7, pp. 3518–3526, 2013.
View at: Publisher Site | Google Scholar
J. S. Biradar and B. S. Sasidhar, “Solvent-free, microwave assisted Knoevenagel condensation of novel 2,5-disubstituted indole analogues and their biological evaluation,” European Journal of Medicinal Chemistry, vol. 46, no. 12, pp. 6112–6118, 2011.
View at: Publisher Site | Google Scholar
J. S. Biradar, B. S. Sasidhar, and R. Parveen, “Synthesis, antioxidant and DNA cleavage activities of novel indole derivatives,” European Journal of Medicinal Chemistry, vol. 45, no. 9, pp. 4074–4078, 2010.
View at: Publisher Site | Google Scholar
J. S. Biradar, R. Parveen, B. S. Sasidhar, and S. M. Praveen, “Synthesis of new indolyl benzodiazepines and their DNA cleavage and antimicrobial activities,” Indian Journal of Heterocyclic Chemistry, vol. 20, pp. 181–182, 2010.
View at: Google Scholar
J. S. Biradar, Studies in the indole field [Ph.D. thesis], Gulbarga University, Gulbarga, India, 1982.
R. P. Singh, K. N. C. Murthy, and G. K. Jayaprakasha, “Studies on the antioxidant activity of pomegranate (Punica granatum) peel and seed extracts using in vitro models,” Journal of Agricultural and Food Chemistry, vol. 50, no. 1, pp. 81–86, 2002.
View at: Publisher Site | Google Scholar
C. Praveen, A. Ayyanar, and P. T. Perumal, “Practical synthesis, anticonvulsant, and antimicrobial activity of N-allyl and N-propargyl di(indolyl)indolin-2-ones,” Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 13, pp. 4072–4077, 2011.
View at: Publisher Site | Google Scholar
K. Mruthunjaya and V. I. Hukkeri, “In vitro antioxidant and free radical scavenging potential of Parkinsonia aculeata Linn,” Pharmacognosy Magazine, vol. 4, no. 13, pp. 42–51, 2008.
View at: Google Scholar
J. C. M. Barreira, I. C. F. R. Ferreira, M. B. P. P. Oliveira, and J. A. Pereira, “Antioxidant activity and bioactive compounds of ten Portuguese regional and commercial almond cultivars,” Food and Chemical Toxicology, vol. 46, no. 6, pp. 2230–2235, 2008.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2014 Jaiprakash Sharanappa Biradar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

939

Downloads

877

Citations